The article by Jalowy et al. (1) supports the hypothesis that the cardioprotective effect of AT 1 -receptor blockade involves angiotensin II-induced AT 2 -receptor activation, bradykinin and prostaglandins. This vascular mechanism (AT 1 -receptor activation mediates proliferation and vasoconstriction, and AT 2 -receptor activation opposes these) might be especially important in patients with heart failure where AT 2 -receptors are dominant (2). The authors insightfully highlighted the conflicting results of AT 1 -blockade in different experimental models (1). Unfortunately, they confused AT 1 -and AT 2 -receptors (page 1787, second column, second paragraph, lines 3 to 11; page 1792, first column, line 7) and made erroneous statements about AT 1 -and AT 2 -receptor activation and blockade. Thus, on page 1787, AT 2 -receptor activation (not AT 1 ) increases kinin formation in isolated dog coronary arteries; attenuation of left ventricular dilatation after myocardial infarction in rats by AT 1 -receptor blockade is abolished by AT 2 -receptor blockade (not AT 1 ); a kinin-mediated mechanism secondary to activation of the AT 2 -receptor may contribute to cardioprotection achieved by AT 1 -receptor blockade (not AT 2 ).
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The finding of a dramatic reduction in infarct size after only 30 min of pretreatment with intravenous candesartan (an AT 1 -receptor antagonist) in an in vivo, anesthetized minipig model of 90-min "low-flow ischemia" and 120-min reperfusion (1) also confirms reports of in vitro evidence of cardioprotection after chronic pretreatment (Ͼ30 min) with AT 1 -receptor antagonists. However, patient groups in whom benefits of pretreatment might be applicable need to be identified and studied. One such group is the hypertensive patient who is prone to develop an acute coronary syndrome and who is already on an AT 1 -receptor blocker.
The authors (1) did not mention that dramatic myocardial salvage and limitation of early remodeling with the AT 1 -receptor antagonist L-158,809, given intravenously for 48 h (0.1 mg/kg bolus and 0.6 mg/kg/min infusions) after anterior myocardial infarction in the in vivo dog model, has already been reported (3). However, Jalowy et al. (1) elegantly produced coronary hypoperfusion in the minipig by adjusting a roller pump to reduce systolic thickening (ultrasonic crystals) by Ͼ90%. Although they measured transmural flow (radioactive microspheres) in samples from the site of the crystals, their finding of decreased infarct size (albeit using the TTC [triphenyl tetrazolium chloride] technique) (1) underscores the cardioprotective effect of AT 1 -receptor blockade in models of low-flow ischemia (in dogs). It is pertinent that a pig heart has poorly developed collaterals (resembling patients without longstanding coronary disease or ischemia) so that acute coronary occlusion results in no reflow ischemia (4) . In contrast, a dog heart has a rich collateral supply (resembling patients with longstanding coronary disease and ischemia) so that acute coronary occlusion results in low-flow ischemia (5) . The argument that low-flow allowed the drugs (PD 123,319 i.c., HOE-140 i.c. and indomethacin i.v. given before and during ischemia) to reach the ischemic zone in their modified minipig model (1) is therefore probably valid. However, because Jalowy et al. (1) only report transmural flow after 90-min ischemia but not flow (or hemodynamics) after 120 min of reperfusion, one cannot be certain of "reflow" or "no-reflow" in their model.
The demonstration of a decrease in slope of the relation between flow after 5 min of ischemia and subsequent infarct size (as percent of risk region) with candesartan (1) is interesting. However, a similar effect between flow after 90-min ischemia and 120-min reperfusion (when infarct size was measured) would have been more convincing. Demonstration of a reduction of the slope of the relation between infarct size (after ischemia and reperfusion) and the risk region (6) would have provided definitive evidence of myocardial salvage with candesartan.
Jalowy et al. also hinted on the converse hypothesis (page 1792, first column) whereby AT 2 -receptor blockade might redistribute AngII toward AT 1 -receptors and cause their activation (1). However, AT 2 -receptor blockade with PD 123,319 did not increase infarct size, but rather, suggested a slight reduction that was not statistically significant (1) . They acknowledged that acute AT 2 -receptor blockade is cardioprotective in the in vitro isolated working heart model, where AT 1 -receptor blockade has a deleterious effect on recovery of contractile function (1,7). They recognized that an AT 1 -receptor-mediated positive inotropic effect on the myocardium is the most likely mechanism for this previously reported improvement of contractile function with AT 2 -receptor blockade after ischemia-reperfusion (7). This AT 1 -receptormediated, nonvascular, second mechanism of cardioprotection might be important and requires further study.
